Engel-Nitz Nicole M, Hao Yanni, Becker Laura K, Gerdes Randall
Senior Researcher, Optum, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA.
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
J Comp Eff Res. 2015 Aug;4(4):303-14. doi: 10.2217/cer.15.19.
To examine cost and mortality differences in postmenopausal women with HR(+)/HER2(-) advanced breast cancer.
Using claims data (2007-2013), women with newly diagnosed (de novo) stage IV, or early- or late-recurring metastatic breast cancer were identified.
Compared with de novo (n = 121) and late-recurrent (n = 106), early-recurrent (n = 172) patients had significantly higher costs in total and for anticancer systemic agents. Adjusted per patient per month costs for early-recurrent patients were US$13,404, versus US$9955 (de novo) and US$9721 (late-recurrent; p = 0.02). Early-recurrent patients' risk of death was twice that of de novo patients (p = 0.02).
Compared with new diagnosis or late recurrence, early recurrence of HR+/HER2- metastatic breast cancer was associated with higher mortality and healthcare costs.
研究绝经后HR(+)/HER2(-)晚期乳腺癌患者的成本和死亡率差异。
利用索赔数据（2007 - 2013年），确定新诊断（初发）IV期、早期或晚期复发性转移性乳腺癌患者。
与初发患者（n = 121）和晚期复发患者（n = 106）相比，早期复发患者（n = 172）的总成本和抗癌全身用药成本显著更高。早期复发患者调整后的人均每月成本为13404美元，而初发患者为9955美元，晚期复发患者为9721美元（p = 0.02）。早期复发患者的死亡风险是初发患者的两倍（p = 0.02）。
与新诊断或晚期复发相比，HR+/HER2-转移性乳腺癌的早期复发与更高的死亡率和医疗成本相关。
